Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BiomX Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

BiomX şirketinin toplam hissedar öz sermayesi $27.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $68.6M ve $41.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$31.61m
Eşitlik	US$27.43m
Toplam yükümlülükler	US$41.19m
Toplam varlıklar	US$68.62m

Son finansal sağlık güncellemeleri

Recent updates

What Kind Of Shareholders Own BiomX Inc. (NYSEMKT:PHGE)?

Jan 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PHGE 'nin kısa vadeli varlıkları ( $35.1M ) kısa vadeli yükümlülüklerini ( $7.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: PHGE şirketinin kısa vadeli varlıkları ( $35.1M ) uzun vadeli yükümlülüklerini ( $33.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PHGE borçsuzdur.

Borcun Azaltılması: PHGE un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PHGE şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: PHGE un, serbest nakit akışı her yıl % 10.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

BiomX Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

BiomX Announces NYSE American Acceptance of Plan to Regain Listing Compliance

BiomX Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BiomX Inc. announced delayed annual 10-K filing

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BiomX Inc. announced delayed 10-Q filing

Recent updates

BiomX Inc. to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Biomx Inc. to Present Positive Phase 1B/2A Clinical Trial Data for Bx004 At the European Respiratory Society (Ers) Congress 2024

New major risk - Financial position

High number of new directors

BiomX Announces NYSE American Acceptance of Plan to Regain Listing Compliance

BiomX Inc., Annual General Meeting, Jul 09, 2024

BiomX Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BiomX Inc. to Report Q1, 2024 Results on May 21, 2024

Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board

BiomX Inc. announced delayed annual 10-K filing

BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC

BiomX Inc. announced that it expects to receive $50.013969 million in funding

BiomX Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis

BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors

BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference

Biomx Inc. Appoints Jason M. Marks and Michael E. Dambach to the Board of Directors

BiomX Inc. Announces Board Resignations

BiomX Inc. Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BiomX Inc. Announces Dosing of the First Two Patients in Phase 1B/2A Study of Bx004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

BiomX Inc., Annual General Meeting, Aug 24, 2022

Price target decreased to US$10.25

BiomX Inc. to Report Q1, 2022 Results on May 11, 2022

CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

Price target decreased to US$19.00

High number of new directors

BiomX Inc. announced delayed 10-Q filing

BiomX Inc. Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

New 90-day high: US$8.40

New 90-day high: US$7.11

BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy

What Kind Of Shareholders Own BiomX Inc. (NYSEMKT:PHGE)?

New 90-day high: US$6.97

BiomX Inc. Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer

New 90-day high: US$6.67

BiomX Inc. Presents Preclinical Results of Phage Targeting Klebsiella Pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

BiomX Inc. to Report Q3, 2020 Results on Nov 12, 2020

BiomX Reports Appointment of Paul Sekhri and Alan Moses to Its Board of Directors

Biomx Inc. Announces Changes to Its Board

New 90-day high - US$8.00

BiomX Inc. to Report Q2, 2020 Results on Aug 13, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin